How orphan designated drugs private equity performed in the pharmaceutical industry in Q2 2023
In value terms, orphan designated drugs-related deal activity increased by 2248% in Q2 2023 compared with the previous quarter’s total of $22.8m and fell by 56% as compared to Q2 2022. Related deal volume increased by 133% in Q2 2023 versus the previous quarter and was 42% lower than in Q2 2022.
The top-ranked legal advisors supporting these private equity deals in Q2 2023 were Goodwin Procter; Latham & Watkins; Lefevre Pelletier & associes, Avocats with 1, 1, 1 deals respectively.
For further understanding of GlobalData’s New Drug Approvals and Their Contract Manufacture – 2023 Edition buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.
Source link
#orphan #designated #drugs #private #equity #performed #pharmaceutical #industry
